News

Xhance is the first medication indicated for the treatment of chronic rhinosinusitis without nasal polyps to be approved by the FDA.

The latest news for pharma industry insiders.

In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, discusses the positive signs from rising activity levels in biopharma M&A— and what the momentum may mean for industry dealmaking and partnership efforts in the months ahead.

Reliance on foreign imports means that disruptions in the supply chain can profoundly impact the ability of individuals in the United States to get access to the medications they need.

The latest news for pharma industry insiders.

Biosimilars market experiences massive growth, but regulatory and adoption challenges remain.

Approval was based on positive data from the Phase III MARCH study across a range of genetic progressive familial intrahepatic cholestasis types.

This financial toxicity is quite prominent, but what can be done to remedy treatment costs?

Under the group purchasing agreement, the serialization business will be the sole provider of DSCSA services for Premier’s 4,300-plus hospital and health system network.

The latest news for pharma industry insiders.

Steven H. Collis, who currently holds the position, will transition to executive chair of the board.

The Asia-Pacific location is expected to provide serialization solutions for counterfeit medication entering the pharma supply chain.

The latest news for pharma industry insiders.

A sit-down with Groovy Singh, CEO of Bright Green Corporation, who describes the waves in the global supply chain the company is making after being authorized to grow cannabis, along with cannabis-related products.

A qualitative study explores how these drugs are impacting these patients’ lives, while digging deeper into the possibility of deprescribing, with insight from primary care physicians.

The company’s twice-daily, branded ruxolitinib cream 1.5% presents a significant reduction in abscess and inflammatory nodule (AN) count for the treatment of Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa.

A USC study discovers that an increasing share of both generic and brand-name meds are being excluded from approval.

The latest news for pharma industry insiders.

With out-of-pocket healthcare costs resulting in financial issues for patients, a cross-sectional study closely examines whether they are linked to more premature deaths.

A proposed Senate bill is intended to protect citizens’ private health and genetic information.

The latest news for pharma industry insiders.

The contributions consist of multiple investments that aim to boost pandemic preparedness and overall public health protection.

The CDMO’s multi-million-dollar expansion project features commercial manufacturing suites and peptide manufacturing plants.

The latest news for pharma industry insiders.

Navigating the complex landscape of healthcare coverage can be an intimidating task, especially for patients with rare diseases for which treatments often come with a high price tag.

The latest news for pharma industry insiders.

The CDC urges healthcare providers to preserve their current supply.

The pTau217 antibody helps pinpoint pathological changes related to the disease.

The latest news for pharma industry insiders.

Momentum from the previous two years will propel the sector into the rest of 2024, says AM Best analysis.